- Home
- ADCT vs TACH Comparison
ADCT vs TACH Comparison
Compare ADCT & TACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- TACH
- Stock Information
- Founded
- ADCT 2011
- TACH 2024
- Country
- ADCT Switzerland
- TACH United States
- Employees
- ADCT N/A
- TACH N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- TACH
- Sector
- ADCT Health Care
- TACH
- Exchange
- ADCT Nasdaq
- TACH Nasdaq
- Market Cap
- ADCT 380.2M
- TACH 351.2M
- IPO Year
- ADCT 2020
- TACH 2025
- Fundamental
- Price
- ADCT $3.95
- TACH $10.28
- Analyst Decision
- ADCT Strong Buy
- TACH
- Analyst Count
- ADCT 6
- TACH 0
- Target Price
- ADCT $7.60
- TACH N/A
- AVG Volume (30 Days)
- ADCT 860.1K
- TACH 111.3K
- Earning Date
- ADCT 11-10-2025
- TACH 01-01-0001
- Dividend Yield
- ADCT N/A
- TACH N/A
- EPS Growth
- ADCT N/A
- TACH N/A
- EPS
- ADCT N/A
- TACH 0.19
- Revenue
- ADCT $77,246,000.00
- TACH N/A
- Revenue This Year
- ADCT $11.78
- TACH N/A
- Revenue Next Year
- ADCT $4.83
- TACH N/A
- P/E Ratio
- ADCT N/A
- TACH $53.61
- Revenue Growth
- ADCT 15.73
- TACH N/A
- 52 Week Low
- ADCT $1.05
- TACH $10.00
- 52 Week High
- ADCT $4.80
- TACH $10.38
- Technical
- Relative Strength Index (RSI)
- ADCT 44.05
- TACH N/A
- Support Level
- ADCT $3.92
- TACH N/A
- Resistance Level
- ADCT $4.80
- TACH N/A
- Average True Range (ATR)
- ADCT 0.23
- TACH 0.00
- MACD
- ADCT -0.06
- TACH 0.00
- Stochastic Oscillator
- ADCT 4.32
- TACH 0.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.